This document focuses on wound management best practice for diabetic foot ulcers (DFUs). It aims to offer specialists and non-specialists everywhere a practical, relevant clinical guide to appropriate decision making and effective wound healing in people presenting with a DFU.

In recognition of the gap in the literature in the field of wound management, this document concentrates on the importance of wound assessment, debridement and cleansing, recognition and treatment of infection and appropriate dressing selection to achieve optimal healing for patients. However, it acknowledges that healing of the ulcer is only one aspect of management and the role of diabetic control, offloading strategies and an integrated wound care approach to DFU management (which are all covered extensively elsewhere) are also addressed. Prevention of DFUs is not discussed in this document.

The scope of the many local and international guidelines on managing DFUs is limited by the lack of high-quality research. This document aims to go further than existing guidance by drawing, in addition, from the wide-ranging experience of an extensive international panel of expert practitioners. However, it is not intended to represent a consensus, but rather a best practice guide that can be tailored to the individual needs and limitations of different healthcare systems and to suit regional practice.

EXPERT WORKING GROUP

Development group
Paul Chadwick, Principal Podiatrist, Salford Royal Foundation Trust, UK
Michael Edmonds, Professor of Diabetes and Endocrinology, Diabetic Foot Clinic, King’s College Hospital, London, UK
Joanne McCardle, Advanced Clinical and Research Diabetes Podiatrist, NHS Lothian University Hospital, Edinburgh, UK
David Armstrong, Professor of Surgery and Director, Southern Arizona Limb Salvage Alliance (SALSA), University of Arizona College of Medicine, Arizona, USA

Review group
Jan Apelqvist, Senior Consultant, Department of Endocrinology, Skåne University Hospital, Malmo, Sweden
Mariam Botros, Director, Diabetic Foot Canada, Canadian Wound Care Association and Clinical Coordinator, Women’s College Wound Healing Clinic, Toronto, Canada
Giacomo Clerici, Chief Diabetic Foot Clinic, IRCC Casa di Cura Multimedica, Milan, Italy
Jill Cundell, Lecturer/Practitioner, University of Ulster, Belfast Health and Social Care Trust, Northern Ireland
Solang Ehrler, Functional Rehabilitation Department, IUR Clémenceau (Institut Universitaire de Réadaptation Clémenceau), Strasbourg, France
Michael Hummel, MD, Diabetes Center Rosenheim & Institute of Diabetes Research, Helmholtz Zentrum München, Germany
Benjamin A Lipsky, Emeritus Professor of Medicine, University of Washington, USA; Visiting Professor, Infectious Diseases, University of Geneva, Switzerland; Teaching Associate, University of Oxford and Deputy Director, Graduate Entry Course, University of Oxford Medical School, UK
José Luis Lázaro Martínez, Full Time Professor, Diabetic Foot Unit, Complutense University, Madrid, Spain
Rosalyn Thomas, Deputy Head of Podiatry, Abertawe Bro Morgannwg University Health Board, Swansea, Wales
Susan Tulley, Senior Podiatrist, Mafraq Hospital, Abu Dhabi, United Arab Emirates
Introduction

DFUs are complex, chronic wounds, which have a major long-term impact on the morbidity, mortality and quality of patients’ lives\(^1,2\). Individuals who develop a DFU are at greater risk of premature death, myocardial infarction and fatal stroke than those without a history of DFU\(^3\). Unlike other chronic wounds, the development and progression of a DFU is often complicated by wide-ranging diabetic changes, such as neuropathy and vascular disease. These, along with the altered neutrophil function, diminished tissue perfusion and defective protein synthesis that frequently accompany diabetes, present practitioners with specific and unique management challenges\(^1\).

DFUs are relatively common — in the UK, 5–7% of people with diabetes currently have or have had a DFU\(^4,5\). Furthermore, around 25% of people with diabetes will develop a DFU during their lifetime\(^6\). Globally, around 370 million people have diabetes and this number is increasing in every country\(^7\). Diabetes UK estimates that by 2030 some 552 million people worldwide will have diabetes\(^8\).

DFUs have a major economic impact. A US study in 1999 estimated the average outpatient cost of treating one DFU episode as $28,000 USD over a two-year period\(^9\). Average inpatient costs for lower limb complications in 1997 were reported as $16,580 USD for DFUs, $25,241 USD for toe or toe plus other distal amputations and $31,436 USD for major amputations\(^10,11\).

The EURODIALE study examined total direct and indirect costs for one year across several European countries. Average total costs based on 821 patients were approximately 10,000 euros, with hospitalisation representing the highest direct cost. Based on prevalence data for Europe, they estimated that costs associated with treatment of DFUs may be as high as 10 billion euros per year\(^12\).

The EURODIALE study examined total direct and indirect costs for one year across several European countries. Average total costs based on 821 patients were approximately 10,000 euros, with hospitalisation representing the highest direct cost. Based on prevalence data for Europe, they estimated that costs associated with treatment of DFUs may be as high as 10 billion euros per year\(^12\).

In Europe, the annual amputation rate for people with diabetes has been cited as 0.5–0.8\(^%\)\(^1,15\), and in the US it has been reported that around 85% of lower-extremity amputations due to diabetes begin with foot ulceration\(^16,17\). Mortality following amputation increases with level of amputation\(^18\) and ranges from 50–68\% at five years, which is comparable or worse than for most malignancies\(^13,19\) (Figure 1).

The statistics need not make for such grim reading. With appropriate and careful management it is possible to delay or avoid most serious complications of DFUs\(^1\).

**FIGURE 1: Relative five-year mortality (%) (adapted from\(^19\))**

<table>
<thead>
<tr>
<th>Cancer Type</th>
<th>5-Year Mortality</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prostate cancer</td>
<td>97</td>
</tr>
<tr>
<td>Breast cancer</td>
<td>84</td>
</tr>
<tr>
<td>Colon cancer</td>
<td>66</td>
</tr>
<tr>
<td>Ischaemic DFU</td>
<td>48</td>
</tr>
<tr>
<td>Neoplastic D3</td>
<td>47</td>
</tr>
<tr>
<td>Amputation</td>
<td>46</td>
</tr>
<tr>
<td>Neurotic D3</td>
<td>18</td>
</tr>
<tr>
<td>Respiratory failure</td>
<td>18</td>
</tr>
<tr>
<td>Lung cancer</td>
<td>18</td>
</tr>
<tr>
<td>Pancreatic cancer</td>
<td>8</td>
</tr>
</tbody>
</table>

In England, foot complications account for 20\% of the total National Health Service spend on diabetes care, which equates to around £650 million per year (or £1 in every £150)\(^10\). Of course, these figures do not take account of the indirect costs to patients, such as the effect on physical, psychological and social wellbeing and the fact that many patients are unable to work long term as a result of their wounds\(^6\).

A DFU is a pivotal event in the life of a person with diabetes and a marker of serious disease and comorbidities. Without early and optimal intervention, the wound can rapidly deteriorate, leading to amputation of the affected limb\(^5,13\).

It has been estimated that every 20 seconds a lower limb is amputated due to complications of diabetes\(^14\).

In Europe, the annual amputation rate for people with diabetes has been cited as 0.5–0.8\%\(^1,15\), and in the US it has been reported that around 85% of lower-extremity amputations due to diabetes begin with foot ulceration\(^16,17\).

Mortality following amputation increases with level of amputation\(^18\) and ranges from 50–68\% at five years, which is comparable or worse than for most malignancies\(^13,19\) (Figure 1).
It has been suggested that up to 85% of amputations can be avoided when an effective care plan is adopted\textsuperscript{20}. Unfortunately, insufficient training, suboptimal assessment and treatment methods, failure to refer patients appropriately and poor access to specialist footcare teams hinder the prospects of achieving optimal outcomes\textsuperscript{21,22}.

Successful diagnosis and treatment of patients with DFUs involves a holistic approach that includes:
- Optimal diabetes control
- Effective local wound care
- Infection control
- Pressure relieving strategies
- Restoring pulsatile blood flow.

Many studies have shown that planned intervention aimed at healing of DFUs is most effective in the context of a multidisciplinary team with the patient at the centre of this care.

One of the key tenets underpinning this document is that infection is a major threat to DFUs — much more so than to wounds of other aetiologies not subject to diabetic changes. A European-wide study found that 58% of patients attending a foot clinic with a new ulcer had a clinically infected wound\textsuperscript{23}. Similarly a single-centre US study found that about 56% of DFUs were clinically infected\textsuperscript{24}. This study also showed the risk of hospitalisation and lower-extremity amputation to be 56–155 times greater for diabetes patients with a foot infection than those without\textsuperscript{24}.

Recognising the importance of starting treatment early may allow practitioners to prevent progression to severe and limb-threatening infection and potentially halt the inevitable pathway to amputation\textsuperscript{25}.

This document offers a global wound care plan for practitioners (page 20), which includes a series of steps for preventing complications through active management — namely prompt and appropriate treatment of infection, referral to a vascular specialist to manage ischaemia and optimal wound care. This should be combined with appropriate patient education and an integrated approach to care.
Aetiology of DFUs

The underlying cause(s) of DFUs will have a significant bearing on the clinical management and must be determined before a care plan is put into place.

In most patients, peripheral neuropathy and peripheral arterial disease (PAD) (or both) play a central role and DFUs are therefore commonly classified as (Table 1)26:

- Neuropathic
- Ischaemic
- Neuroischaemic (Figures 2–4).

Neuroischaemia is the combined effect of diabetic neuropathy and ischaemia, whereby macrovascular disease and, in some instances, microvascular dysfunction impair perfusion in a diabetic foot26,27.

PERIPHERAL NEUROPATHY
Peripheral neuropathy may predispose the foot to ulceration through its effects on the sensory, motor and autonomic nerves:

- The loss of protective sensation experienced by patients with sensory neuropathy renders them vulnerable to physical, chemical and thermal trauma
- Motor neuropathy can cause foot deformities (such as hammer toes and claw foot), which may result in abnormal pressures over bony prominences
- Autonomic neuropathy is typically associated with dry skin, which can result in fissures, cracking and callus. Another feature is bounding pulses, which is often misinterpreted as indicating a good circulation28.

Loss of protective sensation is a major component of nearly all DFUs29,30. It is associated with a seven-fold increase in risk of ulceration6.

Patients with a loss of sensation will have decreased awareness of pain and other symptoms of ulceration and infection31.

PERIPHERAL ARTERIAL DISEASE
People with diabetes are twice as likely to have PAD as those without diabetes32. It is also a key risk factor for lower extremity amputation30. The proportion of patients with an ischaemic component to their DFU is increasing and it is reported to be a contributory factor in the development of DFUs in up to 50% of patients14,28,33.

It is important to remember that even in the absence of a poor arterial supply, microangiopathy (small vessel dysfunction) contributes to poor ulcer healing in neuroischaemic DFUs34. Decreased perfusion in the diabetic foot is a complex scenario and is characterised by various factors relating to microvascular dysfunction in addition to PAD34.

DFUs usually result from two or more risk factors occurring together. Intrinsic elements such as neuropathy, PAD and foot deformity (resulting, for example, from neuropathic structural changes), accompanied by an external trauma such as poorly fitting footwear or an injury to the foot can, over time, lead to a DFU7.

### TABLE 1: Typical features of DFUs according to aetiology

<table>
<thead>
<tr>
<th>Feature</th>
<th>Neuropathic</th>
<th>Ischaemic</th>
<th>Neuroischaemic</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sensation</td>
<td>Sensory loss</td>
<td>Painful</td>
<td>Degree of sensory loss</td>
</tr>
<tr>
<td>Callus/necrosis</td>
<td>Callus present and</td>
<td>Necrosis common</td>
<td>Minimal callus</td>
</tr>
<tr>
<td></td>
<td>often thick</td>
<td></td>
<td>Prone to necrosis</td>
</tr>
<tr>
<td>Wound bed</td>
<td>Pink and granulating</td>
<td>Pale and sloughy</td>
<td>Poor granulation</td>
</tr>
<tr>
<td></td>
<td>surrounded by callus</td>
<td>with poor granulation</td>
<td></td>
</tr>
<tr>
<td>Foot temperature and pulses</td>
<td>Warm with bounding</td>
<td>Cool with absent</td>
<td>Cool with absent pulses</td>
</tr>
<tr>
<td></td>
<td>pulses</td>
<td>pulses</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td>Dry skin and</td>
<td>Delayed healing</td>
<td>High risk of infection</td>
</tr>
<tr>
<td></td>
<td>fissuring</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Typical location</td>
<td>Weight-bearing</td>
<td>Tips of toes, nail</td>
<td>Margins of the foot and</td>
</tr>
<tr>
<td></td>
<td>areas of the foot,</td>
<td>edges and between</td>
<td>toes</td>
</tr>
<tr>
<td></td>
<td>such as metatarsal</td>
<td>the toes and lateral</td>
<td></td>
</tr>
<tr>
<td></td>
<td>heads, the heel and</td>
<td>borders of the foot</td>
<td></td>
</tr>
<tr>
<td></td>
<td>over the dorsum of</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>clawed toes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prevalence (based on35)</td>
<td>35%</td>
<td>15%</td>
<td>50%</td>
</tr>
</tbody>
</table>

FIGURE 2: Neuropathic DFU

FIGURE 3: Ischaemic DFU

FIGURE 4: Neuroischaemic DFU
ASSESSING DFUs

Assessing DFUs

Patients with a DFU need to be assessed holistically and intrinsic and extrinsic factors considered

For the non-specialist practitioner, the key skill required is knowing when and how to refer a patient with a DFU to the multidisciplinary foot-care team (MDFT; see page 19). Patients with a DFU should be assessed by the team within one working day of presentation — or sooner in the presence of severe infection. In many places, however, MDFTs do not exist and practitioners instead work as individuals. In these situations, the patient’s prognosis often depends on a particular practitioner’s knowledge and interest in the diabetic foot.

Patients with a DFU need to be assessed holistically to identify intrinsic and extrinsic factors. This should encompass a full patient history including medication, comorbidities and diabetes status. It should also take into consideration the history of the wound, previous DFUs or amputations and any symptoms suggestive of neuropathy or PAD.

EXAMINATION OF THE ULCER

A physical examination should determine:

- Is the wound predominantly neuropathic, ischaemic or neuroischaemic?
- If ischaemic, is there critical limb ischaemia?
- Are there any musculoskeletal deformities?
- What is the size/depth/location of the wound?
- What is the colour/status of the wound bed?
  - Black (necrosis)
  - Yellow, red, pink
- Is there any exposed bone?
- Is there any necrosis or gangrene?
- Is the wound infected? If so, are there systemic signs and symptoms of infection (such as fevers, chills, rigors, metabolic instability and confusion)?
- Is there any malodour?
- Is there local pain?
- Is there any exudate? What is the level of production (high, moderate, low, none), colour and consistency of exudate, and is it purulent?
- What is the status of the wound edge (callus, maceration, erythema, oedema, undermining)?

Documenting ulcer characteristics

Recording the size, depth, appearance and location of the DFU will help to establish a baseline for treatment, develop a treatment plan and monitor any response to interventions. It is important also to assess the area around the wound: erythema and maceration indicate additional complications that may hinder wound healing.

Digitally photographing DFUs at the first consultation and periodically thereafter to document progress is helpful. This is particularly useful for ensuring consistency of care among healthcare practitioners, facilitating telehealth in remote areas and illustrating improvement to the patient.

TESTING FOR LOSS OF SENSATION

Two simple and effective tests for peripheral neuropathy are commonly used:

- 10g (Semmes-Weinstein) monofilament
- Standard 128Hz tuning fork

The 10g monofilament is the most frequently used screening tool to determine the presence of neuropathy in patients with diabetes. It should be applied at various sites along the plantar aspect of the foot. Guidelines vary in the number of sites advocated, but the international consensus is to test at three sites (see Figure 5). A positive result is the inability to feel the monofilament when it is pressed against the foot with enough force to bend it.

Neuropathy is also demonstrated by an inability to sense vibration from a standard tuning fork. Other tests are available, such as the biothesiometer and neurothesiometer, which are more complex handheld devices for assessing the perception of vibration.

Do not test for neuropathy in areas of callus as this can mask feeling from any of the neuropathy testing devices and may give a false-positive result.

Be aware that patients with small nerve fibre damage and intact sensory nerves may have
a painful neuropathy. They may describe sharp, stabbing, burning, shooting or electric shock type pain, which may be worse at night and can disrupt sleep. The absence of cold-warm discrimination may help to identify patients with small nerve fibre damage.

**TESTING FOR VASCULAR STATUS**

Palpation of peripheral pulses should be a routine component of the physical examination and include assessment of the femoral, popliteal and pedal (dorsalis pedis and posterior tibial) pulses. Assessment of pulses is a learned skill and has a high degree of inter-observer variability, with high false-positive and false-negative rates. The dorsalis pedis pulse is reported to be absent in 8.1% of healthy individuals, and the posterior tibial pulse is absent in 2.0%. Nevertheless, the absence of both pedal pulses, when assessed by an experienced clinician, strongly suggests the presence of pedal vascular disease. If there is any doubt regarding diagnosis of PAD, it is important to refer to a specialist for a full vascular assessment.

Where available, Doppler ultrasound, ankle-brachial pressure index (ABPI) and Doppler waveform may be used as adjuncts to the clinical findings when carried out by a competent practitioner. Toe pressures, and in some instances, transcutaneous oxygen measurement (where equipment is available), may be useful for measuring local tissue perfusion.

An ischaemic foot may appear pink and relatively warm even with impaired perfusion due to arteriovenous shunting. Delayed discoloration (rubor) or venous refilling greater than five seconds on dependency may indicate poor arterial perfusion.

**COMMON TERMS EXPLAINED**

- **Critical limb ischaemia**: this is a chronic manifestation of PAD where the arteries of the lower extremities are severely blocked. This results in ischaemic pain in the feet or toes even at rest. Complications of poor circulation include skin ulcers or gangrene. If left untreated it will result in amputation of the affected limb.

- **Acute limb ischaemia**: this occurs when there is a sudden lack of blood flow to a limb and is due to either an embolism or thrombosis. Without surgical revascularisation, complete acute ischaemia leads to extensive tissue necrosis within six hours.

---

**FIGURE 5: Procedure for carrying out the monofilament test (adapted from**

The International Working Group on the Diabetic Foot (IWGDF) recommends the following procedure for carrying out the monofilament test.

- The sensory examination should be carried out in a quiet and relaxed setting
- The patient should close their eyes so as not to see whether or where the examiner applies the monofilament
- The patient should sit supine with both feet level
- First apply the monofilament on the patient’s hands or on the inside of the arm so they know what to expect
- Apply the monofilament perpendicular to the skin surface with sufficient force to bend or buckle the monofilament
- Ask the patient:
  - Whether they feel the pressure applied (yes/no)
  - Where they feel the pressure (left foot/right foot)
- Apply the monofilament along the perimeter of (not on) the ulcer site
- Do not allow the monofilament to slide across the skin or make repetitive contact at the test site
- The total duration of the approach (skin contact and removal of the monofilament) should be around 2 seconds
- Apply the monofilament to each site three times, including at least one additional ‘mock’ application in which no filament is applied
- Encourage the patient during testing by giving positive feedback
  - Protective sensation is present at each site if the patient correctly answers two out of three applications
  - Protective sensation is absent with two out of three incorrect answers

Note: The monofilament should not be used on more than 10 patients without a recovery period of 24 hours.
usually exercise-induced (although this is often absent in people with diabetes)
■ A temperature difference between the feet.

If you suspect severe ischaemia in a patient with a DFU you should refer as quickly as possible to a MDFT with access to a vascular surgeon. If the patient has critical limb ischaemia this should be done urgently. A patient with acute limb ischaemia characterised by the six ‘Ps’ (pulselessness, pain, pallor (mottled colouration), peri...
Cultures should not be taken from clinically non-infected wounds as all ulcers will be contaminated; microbiological sampling cannot discriminate colonisation from infection.

Extensive inflammation, crepitus, bullae, necrosis or gangrene are signs suggestive of severe foot infections. Refer patients immediately to an MDFT if you suspect a deep or limb-threatening infection. Where there is no MDFT, the referral should be to the most appropriate practitioner, notably the person(s) championing the cause of the diabetic foot, for example an experienced foot surgeon.

Refer patients urgently to a member of the specialist foot care team for urgent surgical treatment and prompt revascularisation if there is acute spreading infection (Box 1), critical limb ischaemia, wet gangrene or an unexplained hot, red, swollen foot with or without the presence of pain. These clinical signs and symptoms are potentially limb- and even life-threatening.

Where necrosis occurs on the distal part of the limb due to ischaemia and in the absence of infection (dry gangrene), mummification of the toes and auto-amputation may occur. In most of these situations, surgery is not recommended. However, if the necrosis is more superficial then the toe can be removed with a scalpel (Figure 6).

Assessing bone involvement
Osteomyelitis may frequently be present in patients with moderate to severe diabetic foot infection. If any underlying osteomyelitis is not identified and treated appropriately, the wound is unlikely to heal.

Osteomyelitis can be difficult to diagnose in the early stages. Wounds that are chronic, large, deep or overlie a bony prominence are at high risk for underlying bone infection, while the presence of a ‘sausage toe’ or visible bone is suggestive of osteomyelitis. A simple clinical test for bone infection is detecting bone by its hard, gritty feel when gently inserting a sterile blunt metal probe into the ulcer. This can help to diagnose bone infection (when the likelihood is high) or exclude (when the likelihood is low).

Plain x-rays can help to confirm the diagnosis, but they have a relatively low sensitivity (early in the infection) and specificity (late in the course of infection) for osteomyelitis.

The National Institute for Health and Care Excellence (NICE) in the UK and IDSA recommend that if initial x-rays do not confirm the presence of osteomyelitis and suspicion remains high, the next advanced imaging test to consider is magnetic resonance imaging (MRI). If MRI is contraindicated or unavailable, white blood cell scanning combined with a radionuclide bone scan may be performed instead. The most definitive way to diagnose osteomyelitis is by the combined findings of culture and histology from a bone specimen. Bone may be obtained during deep debridement or by biopsy.

INSPECTING FEET FOR DEFORMITIES
Excessive or abnormal plantar pressure, resulting from limited joint mobility, often combined with foot deformities, is a common underlying cause of DFUs in individuals with neuropathy. These patients may also develop atypical walking patterns (Figure 7). The resulting altered biomechanical loading of the foot can result in callus, which increases the abnormal pressure and can cause subcutaneous haemorrhage. Because there is commonly loss of sensation, the patient continues to walk on the foot, increasing the risk of further problems.

Typical presentations resulting in high plantar pressure areas in patients with motor neuropathy are:

- A high-arch foot
- Clawed lesser toes
- Visible muscle wasting in the plantar arch and on the dorsum between the metatarsal shafts (a ‘hollowed-out’ appearance)
- Gait changes, such as the foot ‘slapping’ on the ground
- Hallux valgus, hallux rigidus and fatty pad depletion.

In people with diabetes, even minor trauma can precipitate a chronic ulcer. This might be caused by wearing poorly fitting footwear or walking barefoot, or from an acute injury. In some cultures the frequent adoption of the prayer position and/or sitting cross-legged will cause ulcerations on the lateral malleolus, and to a lesser extent the dorsum of the foot, in the mid-tarsal area. The dorsal, plantar and posterior surfaces of both feet and between the toes should be checked thoroughly for breaks in the skin or newly established DFUs.
Charcot joint is a form of neuroarthropathy that occurs most often in the foot and in people with diabetes. Nerve damage from diabetes causes decreased sensation, muscle atrophy and subsequent joint instability, which is made worse by walking on an insensitive joint. In the acute stage there is inflammation and bone reabsorption, which weakens the bone. In later stages, the arch falls and the foot may develop a ‘rocker bottom’ appearance (Figure 8). Early treatment, particularly offloading pressure, can help stop bone destruction and promote healing.

Corrective foot surgery to offload pressure areas may be considered where structural deformities cannot be accommodated by therapeutic footwear.

### Classification of DFUs

Classification systems grade ulcers according to the presence and extent of various physical characteristics, such as size, depth, appearance and location. They can help in the planning and monitoring of treatment and in predicting outcome, and also for research and audit.

Classification systems should be used consistently across the healthcare team and be recorded appropriately in the patient’s records. However, it is the assessment of the wound that informs management.

Table 3 summarises the key features of the systems most commonly used for DFUs.

<table>
<thead>
<tr>
<th>Classification system</th>
<th>Key points</th>
<th>Pros/cons</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wagner</td>
<td>Assesses ulcer depth along with presence of gangrene and loss of perfusion using six grades (0-5)</td>
<td>Well established&lt;sup&gt;56&lt;/sup&gt; &lt;br&gt; Does not fully address infection and ischaemia</td>
<td>Wagner 1981&lt;sup&gt;59&lt;/sup&gt;</td>
</tr>
<tr>
<td>University of Texas (Armstrong)</td>
<td>Assesses ulcer depth, presence of infection and presence of signs of lower-extremity ischaemia using a matrix of four grades combined with four stages</td>
<td>Well established&lt;sup&gt;56&lt;/sup&gt; &lt;br&gt; Describes the presence of infection and ischaemia better than Wagner and may help in predicting the outcome of the DFU</td>
<td>Lavery et al 1996&lt;sup&gt;60&lt;/sup&gt; &lt;br&gt; Armstrong et al 1998&lt;sup&gt;52&lt;/sup&gt;</td>
</tr>
<tr>
<td>PEDIS</td>
<td>Assesses Perfusion, Extent (size), Depth (tissue loss), Infection and Sensation (neuropathy) using four grades (1-4)</td>
<td>Developed by IWGDF &lt;br&gt; User-friendly (clear definitions, few categories) for practitioners with a lower level of experience with diabetic foot management</td>
<td>Lipsky et al 2012&lt;sup&gt;64&lt;/sup&gt;</td>
</tr>
<tr>
<td>SINBAD</td>
<td>Assesses Site, Ischaemia, Neuropathy, Bacterial infection and Depth &lt;br&gt; Uses a scoring system to help predict outcomes and enable comparisons between different settings and countries</td>
<td>Simplified version of the S(AD)SAD classification system&lt;sup&gt;61&lt;/sup&gt; &lt;br&gt; Includes ulcer site as data suggests this might be an important determinant of outcome&lt;sup&gt;62&lt;/sup&gt;</td>
<td>Ince et al 2008&lt;sup&gt;63&lt;/sup&gt;</td>
</tr>
</tbody>
</table>
**DFU wound management**

Practitioners must strive to prevent DFUs developing elsewhere on the foot or on the contralateral limb and to achieve limb preservation.\(^6^4\)

The principle aim of DFU management is wound closure. More specifically, the intention should be to treat the DFU at an early stage to allow prompt healing.\(^6^5\)

The essential components of management are:
- Treating underlying disease processes
- Ensuring adequate blood supply
- Local wound care, including infection control
- Pressure offloading.

Effective foot care should be a partnership between patients, carers and healthcare professionals.\(^1,6^6\) This means providing appropriate information to enable patients and carers to participate in decision making and understand the rationale behind some of the clinical decisions as well as supporting good self-care.

**TREATING THE UNDERLYING DISEASE PROCESSES**

Practitioners should identify the underlying cause of the DFU during the patient assessment and, where possible, correct or eliminate it.
- Treating any severe ischaemia is critical to wound healing, regardless of other interventions.\(^1^7\) It is recommended that all patients with critical limb ischaemia, including rest pain, ulceration and tissue loss, should be referred for consideration of arterial reconstruction.\(^3^1\)
- Achieving optimal diabetic control. This should involve tight glycaemic control and managing risk factors such as high blood pressure, hyperlipidaemia and smoking.\(^6^7\) Nutritional deficiencies should also be managed.\(^7\)
- Addressing the physical cause of the trauma. As well as examining the foot, practitioners should examine the patient’s footwear for proper fit, wear and tear and the presence of any foreign bodies (such as small stones, glass fragments, drawing pins, pet hairs) that may traumatise the foot.\(^1\) When possible and appropriate, practitioners should check other footwear worn at home and at work (e.g., slippers and work boots).

**ENSURING ADEQUATE BLOOD SUPPLY**

A patient with acute limb ischaemia (see page 5) is a clinical emergency and may be at great risk if not managed in a timely and effective way.

It is important to appreciate that, aside from critical limb ischaemia, decreased perfusion or impaired circulation may be an indicator for revascularisation in order to achieve and maintain healing and to avoid or delay a future amputation.\(^3^4\)

**OPTIMISING LOCAL WOUND CARE**

The European Wound Management Association (EWMA) states that the emphasis in wound care for DFUs should be on radical and repeated debridement, frequent inspection and bacterial control and careful moisture balance to prevent maceration.\(^4^9\) Its position document on wound bed preparation suggests the following TIME framework for managing DFUs (see also Box 2):
- Tissue debridement
- Inflammation and infection control
- Moisture balance (optimal dressing selection)
- Epithelial edge advancement.

**Tissue debridement**

There are many methods of debridement used in the management of DFUs including surgical/sharp, larval, autolytic and, more recently, hydrosurgery and ultrasonic.\(^6^8,6^9\)

Debridement may be a one-off procedure or it may need to be ongoing for maintenance of the wound bed.\(^6^9\) The requirement for further debridement should be determined at each dressing change. If the wound is not progressing, practitioners should review the current treatment plan and look for an underlying cause of delayed healing (such as microvascular disease).
as ischaemia, infection or inflammation) and consider patient concordance with recommended treatment regimens (such as not wearing offloading devices or not taking antidiabetic medication)\textsuperscript{69}.

**Sharp debridement**

No one debridement method has been shown to be more effective in achieving complete ulcer healing\textsuperscript{70}. However, in practice, the gold standard technique for tissue management in DFUs is regular, local, sharp debridement using a scalpel, scissors and/or forceps\textsuperscript{1,2,7,27,37,71}. The benefits of debridement include\textsuperscript{72}:

- Removes necrotic/sloughy tissue and callus
- Reduces pressure
- Allows full inspection of the underlying tissues
- Helps drainage of secretions or pus
- Helps optimise the effectiveness of topical preparations
- Stimulates healing.

Sharp debridement should be carried out by experienced practitioners (eg a specialist podiatrist or nurse) with specialist training\textsuperscript{22,69}.

Practitioners must be able to distinguish tissue types and understand anatomy to avoid damage to blood vessels, nerves and tendons\textsuperscript{69}. They should also demonstrate high-level clinical decision-making skills in assessing a level of debridement that is safe and effective. The procedure may be carried out in the clinic or at the bedside.

Ulcers may be obscured by the presence of callus. After discussing the plan and expected outcome with the patient in advance, debridement should remove all devitalised tissue, callus and foreign bodies down to the level of viable bleeding tissue\textsuperscript{38,69} (Figures 9 and 10). It is important to debride the wound margins as well as the wound base to prevent the ‘edge effect’, whereby epithelium fails to migrate across a firm, level granulation base\textsuperscript{73,74}.

Sharp debridement is an invasive procedure and can be quite radical. Practitioners must explain fully to patients the risks and benefits of debridement in order to gain their informed consent. One small study piloting an information leaflet showed that many patients did not understand the procedure despite having undergone debridement on several previous occasions\textsuperscript{58}.

Vascular status must always be determined prior to sharp debridement. Patients needing revascularisation should not undergo extensive sharp debridement because of the risk of trauma to vascularly compromised tissues. However, the ‘toothpick’ approach may be suitable for wounds requiring removal of loose callus\textsuperscript{45}. Seek advice from a specialist if in doubt about a patient’s suitability.

**Other debridement methods**

While sharp debridement is the gold standard technique, other methods may be appropriate in certain situations:

- As an interim measure (eg by practitioners without the necessary skill sets to carry out sharp debridement; methods include the use of a monofilament pad or larval therapy)
- For patients for whom sharp debridement is contraindicated or unacceptably painful
- When the clinical decision is that another debridement technique may be more beneficial for the patient
- For patients who have expressed another preference.

**Larval therapy**

The larvae of the greenbottle fly can achieve relatively rapid, atraumatic removal of moist, slimy slough, and can ingest pathogenic organisms present in the wound\textsuperscript{69}. The decision to use larval debridement must be taken by an appropriate specialist practitioner, but the technique itself may then be carried out by generalist or specialist practitioners with minimal training\textsuperscript{69}.

Larval therapy has been shown to be safe and effective in the treatment of DFUs\textsuperscript{75}. However, it is not recommended as the sole method of debridement for neuropathic DFUs as the larvae cannot remove callus\textsuperscript{76}.

A recent review of debridement methods found some evidence to suggest that larval therapy may improve outcomes when compared to autolytic debridement with a hydrogel\textsuperscript{72}.
**Hydrocutaneous debridement** This is an alternative method of wound debridement, which forces water or saline into a nozzle to create a high-energy cutting beam. This enables precise visualisation and removal of devitalised tissue in the wound bed.\(^7\).

**Autolytic debridement** This is a natural process that uses a moist wound dressing to soften and remove devitalised tissue. Care must be taken not to use a moisture-donating dressing as this can predispose to maceration. In addition, the application of moisture-retentive dressings in the presence of ischaemia and/or dry gangrene is not recommended.\(^7\).

Not debriding a wound, not referring a patient to specialist staff for debridement, or choosing the wrong method of debridement, can cause rapid deterioration with potentially devastating consequences.

**Inflammation and infection control**

The high morbidity and mortality associated with infection in DFUs means that early and aggressive treatment — in the presence of even subtle signs of infection — is more appropriate than for wounds of other aetiologies (with the exception of immunocompromised patients) (Table 4, page 12).\(^38\). In one study, nearly half of patients admitted to a specialised foot clinic in France with a diabetic foot infection went on to have a lower-limb amputation.\(^78\).

Both the IDSA\(^46\) and the International Diabetes Federation (IDF) recommend classifying infected DFUs by severity and using this to direct appropriate antibiotic therapy.\(^27\). Clinically uninfected wounds should not be treated with systemic antibiotic therapy. However, virtually all infected wounds require antibiotic therapy.\(^46\).

**Superficial DFUs with skin infection (mild infection)**

For mild infections in patients who have not recently received antibiotic treatment,\(^7,46\):

- Start empiric oral antibiotic therapy targeted at *Staphylococcus aureus* and *β-haemolytic Streptococcus*
- Change to an alternate antibiotic if the culture results indicate a more appropriate antibiotic
- Obtain another optimum specimen for culture if the wound does not respond to treatment.

**Role of topical antimicrobials** The increasing prevalence of antimicrobial resistance (eg meticillin-resistant *S. aureus* (MRSA)) or other complications (eg *Clostridium difficile* infection) has led to a rise in the use of topical antimicrobial treatments for increased wound bioburden.\(^79\) (Box 3). Antimicrobial agents that are used topically have the advantage of not driving resistance. Such agents provide high local concentrations, but do not penetrate intact skin or into deeper soft tissue.\(^80\).

Topical antimicrobials may be beneficial in certain situations:

- Where there are concerns regarding reduced antibiotic tissue penetration — for example, where the patient has a poor vascular supply
- In non-healing wounds where the classic signs and symptoms of infection are absent, but where there is a clinical suspicion of increased bacterial bioburden.

In these situations topical antimicrobials (either alone or as an adjunctive therapy to systemic therapy) have the potential to reduce bacterial load and may protect the wound from further contamination.\(^79\). In addition, treatment at an early stage may prevent spread of infection to deeper tissues.\(^82\). An initial two-week period with regular review is recommended for the use of topical antimicrobials in wounds that are mildly infected or heavily colonised. A recent consensus offers recommendations on appropriate use of silver dressings.\(^83\) If after two weeks:

- There is improvement in the wound, but continuing signs of infection, it may be clinically justifiable to continue the chosen treatment with further regular reviews
- The wound has improved and the signs and symptoms of wound infection are no longer present, the antimicrobial should be discontinued and a non-antimicrobial dressing applied to cover the open wound
- There is no improvement, consider discontinuing the antimicrobial treatment and re-culturing the wound and reassessing the need for surgical therapy or revascularisation.

**BOX 3: Common topical antimicrobial agents that may be considered for use as an adjunctive therapy for diabetic foot infections**

- Silver — dressings containing silver (elemental, inorganic compound or organic complex) or silver sulphadiazine cream/dressings
- Polyhexamethylene biguanide (PHMB) — solution, gel or impregnated dressings
- Iodine — povidone iodine (impregnated dressing) or cadexomer iodine (ointment, beads or impregnated dressings)
- Medical-grade honey — gel, ointment or impregnated dressings

*NB: Topical antimicrobial agents can be used in patients with mild infections to control wound bioburden. They should not be used alone in those with moderate or severe infection.*
TABLE 4: General principles of bacterial management (adapted from 49)

- At initial presentation of infection it is important to assess its severity, take appropriate cultures and consider need for surgical procedures.
- Optimal specimens for culture should be taken after initial cleansing and debride-ment of necrotic tissue.
- Patients with severe infection require empiric broad-spectrum antibiotic therapy, pending culture results. Those with mild (and many with moderate) infection can be treated with a more focused and narrow-spectrum antibiotic.
- Patients with diabetes have immunological disturbances; therefore even bacteria regarded as skin commensals can cause severe tissue damage and should be regarded as pathogens when isolated from correctly obtained tissue specimens.
- Gram-negative bacteria, especially when isolated from an ulcer swab, are often colonising organisms that do not require targeted therapy unless the person is at risk for infection with those organisms.
- Blood cultures should be sent if fever and systemic toxicity are present.
- Even with appropriate treatment, the wound should be inspected regularly for early signs of infection or spreading infection.
- Clinical microbiologists/infectious diseases specialists have a crucial role; laboratory results should be used in combination with the clinical presentation and history to guide antibiotic selection.
- Timely surgical intervention is crucial for deep abscesses, necrotic tissue and for some bone infections.

If there are clinical signs of infection at dressing change, systemic antibiotic therapy should be started. Topical antimicrobials are not indicated as the only anti-infective treatment for moderate or severe infection of deep tissue or bone 38,46.

Patients may also require debridement to remove infected material. In addition, infected wounds should be cleansed at each dressing change with saline or an appropriate antiseptic wound cleansing agent.

**Deep tissue infection (moderate to severe infection)**

For treating deep tissue infection (cellulitis, lymphangitis, septic arthritis, fasciitis):

- Start patients quickly on broad-spectrum antibiotics, commensurate with the clinical history and according to local protocols where possible 37.
- Take deep tissue specimens or aspirates of purulent secretions for cultures at the start of treatment to identify specific organisms in the wound, but do not wait for results before initiating therapy 137.
- Change to an alternate antibiotic if: — indicated by microbiology results 46 — the signs of inflammation are not improving 84.
- Administer antibiotics parenterally for all severe and some moderate infections, and switch to the oral route when the patient is systemically well and culture results are available 46.
- Continue antibiotic therapy until the infection resolves, but not through to complete healing 46. In most cases 1–3 weeks of therapy is sufficient for soft tissue infections.
- Consider giving empiric therapy directed against MRSA 46: — in patients with a prior history of MRSA infection — when the local prevalence of MRSA colonisation or infection is high — if the infection is clinically severe.

Note that the optimal duration of antibiotic treatment is not clearly defined and will depend on the severity of infection and response to treatment 84.

Infection in a neuroischaemic foot is often more serious than in a neuropathic foot (which has a good blood supply), and this should influence antibiotic policy 49. Antibiotic therapy should not be given as a preventive measure in the absence of signs of infection (see Box 4). This is likely to cause infection with more resistant pathogens.

Obtain an urgent consultation with experts (e.g. foot surgeon) for patients who have a rapidly deteriorating wound that is not responding to antibiotic therapy. Infections accompanied by a deep abscess, extensive bone or joint involvement, crepitus, substantial necrosis or gangrene, or necrotising fasciitis, need prompt surgical intervention along with appropriate antibiotic therapy, to reduce the risk of major amputation 51,85.

**Biofilms and chronic persistent infection**

Polymicrobial infections predominate in severe diabetic foot infections and this diversity of bacterial populations in chronic wounds, such as DFUs, may be an important contributor to chronicity 86,87. Biofilms are complex polymicrobial communities that develop on the surface of chronic wounds, which may lack the overt clinical signs of infection 88. They are not visible to the naked eye and cannot be detected by routine cultures 88.

The microbes produce an extra-polymeric substance that contributes to the structure of the biofilm. This matrix acts as a thick, slimy protective barrier, making it very difficult for
antimicrobial agents to penetrate it. The impact of biofilms may depend on which species are present rather than the bioburden.

Treatment should aim to:
- Disrupt the biofilm burden through regular, repeated debridement and vigorous wound cleansing
- Prevent reformation and attachment of the biofilm by using antimicrobial dressings.

Appropriate wound bed preparation remains the gold standard for biofilm removal.

**Moisture balance: optimal dressing selection**

Most dressings are designed to create a moist wound environment and support progression towards wound healing. They are not a substitute for sharp debridement, managing systemic infection, offloading devices and diabetic control.

Moist wound healing has the potential to address multiple factors that affect wound healing. It involves maintaining a balanced wound environment that is not too moist or too dry. Dressings that can help to manage wound exudate optimally and promote a balanced environment are key to improving outcomes. However, a dressing that may be ideal for wounds of other aetiologies may be entirely inappropriate for certain DFUs. The dressing selected may have a considerable effect on outcome and, due to the varying complexities of DFUs, there is no single dressing to suit all scenarios.

Many practitioners are confused by the great range of dressings available. Impressive claims are rarely supported by scientific studies and there is often a lack of high-quality evidence to support decision making. One inherent problem is whether the characteristics of each wound randomised to a specific dressing in a trial correspond to the characteristics that the dressing was designed to manage. Many dressings are designed for non-foot areas of the body and may be difficult to apply between or over the toes or plantar surface. In addition, most practitioners have historically had little specific, practical guidance on selecting dressings.

In the absence of strong evidence of clinical or cost effectiveness, healthcare professionals should use wound dressings that best match the clinical appearance and site of the wound, as well as patient preferences. Dressing choice must begin with a thorough patient and wound assessment. Factors to consider include:
- Location of the wound
- Extent (size/depth) of the wound
- Amount and type of exudate
- The predominant tissue type on the wound surface
- Condition of the periwound skin
- Compatibility with other therapies (eg contact casts)
- Wound bioburden and risk of infection
- Avoidance of pain and trauma at dressing changes
- Quality of life and patient wellbeing.

The status of the diabetic foot can change very quickly, especially if infection has not been appropriately addressed. The need for regular inspection and assessment means that dressings designed to be left in situ for more than five days are not usually appropriate for DFU management.

Practitioners should also consider the following questions.

**Does the dressing:**
- Stay intact and remain in place throughout wear time?
- Prevent leakage between dressing changes?
- Cause maceration/allergy or sensitivity?
- Reduce pain?
- Reduce odour?
- Retain fluid?
- Trap exudate components?

**Is the dressing:**
- Comfortable, conformable, flexible and of a bulk/weight that can be accommodated in an offloading device/footwear?
- Suitable for leaving in place for the required duration?
- Easy to remove (does not traumatisate the surrounding skin or wound bed)?
- Easy to apply?
- Cost effective?
- Likely to cause iatrogenic lesions?

Tables 5 and 6 (pages 14-15) provide advice on type of dressing and how to select according to tissue type (see also Figures 11-14).
## Table 5: Types of wound dressings available

<table>
<thead>
<tr>
<th>Type</th>
<th>Actions</th>
<th>Indications/use</th>
<th>Precautions/contraindications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alginates/CMC*</td>
<td>Absorb fluid</td>
<td>Moderate to high exuding wounds</td>
<td>Do not use on dry/necrotic wounds. Use with caution on friable tissue (may cause bleeding). Do not pack cavity wounds tightly.</td>
</tr>
<tr>
<td></td>
<td>Promote autolytic debridement</td>
<td>Special cavity presentations in the form of rope or ribbon Combined presentation with silver for antimicrobial activity</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Moisture control</td>
<td>Conformability to wound bed</td>
<td></td>
</tr>
<tr>
<td>Foams</td>
<td>Absorb fluid</td>
<td>Moderate to high exuding wounds</td>
<td>Do not use on dry/necrotic wounds or those with minimal exudate.</td>
</tr>
<tr>
<td></td>
<td>Moisture control</td>
<td>Special cavity presentations in the form of strips or ribbon Combined presentation with silver or PHMB for antimicrobial activity</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Conformability to wound bed</td>
<td>Low adherent versions available for patients with fragile skin Combined presentation with silver or PHMB for antimicrobial activity</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Do not use on dry/necrotic wounds or high exuding wounds May encourage overgranulation May cause maceration</td>
<td></td>
</tr>
<tr>
<td>Honey</td>
<td>Rehydrate wound bed</td>
<td>Sloughy, low to moderate exuding wounds</td>
<td>May cause 'drawing' pain (osmotic effect). Known sensitivity.</td>
</tr>
<tr>
<td></td>
<td>Promote autolytic debridement</td>
<td>Critically colonised wounds or clinical signs of infection</td>
<td></td>
</tr>
<tr>
<td>Hydrocolloids</td>
<td>Absorb fluid</td>
<td>Clean, low to moderate exuding wounds</td>
<td>Do not use on dry/necrotic wounds or high exuding wounds.</td>
</tr>
<tr>
<td></td>
<td>Promote autolytic debridement</td>
<td>Combined presentation with silver for antimicrobial activity</td>
<td>May encourage overgranulation. May cause maceration.</td>
</tr>
<tr>
<td></td>
<td>Antimicrobial action</td>
<td>Low to high exuding wounds</td>
<td></td>
</tr>
<tr>
<td>Hydrogels</td>
<td>Rehydrate wound bed</td>
<td>Low to high exuding wounds</td>
<td>Do not use on highly exuding wounds or where anaerobic infection is suspected. May cause maceration</td>
</tr>
<tr>
<td></td>
<td>Moisture control</td>
<td>Combined presentation with silver for antimicrobial activity</td>
<td></td>
</tr>
<tr>
<td>Iodine</td>
<td>Antimicrobial action</td>
<td>Critically colonised wounds or clinical signs of infection</td>
<td>Do not use on dry necrotic tissue. Known sensitivity to iodine. Short-term use recommended (risk of systemic absorption).</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Low to high exuding wounds</td>
<td></td>
</tr>
<tr>
<td>Low-adherent wound contact layer (silicone)</td>
<td>Protect new tissue growth</td>
<td>Low to high exuding wounds</td>
<td>May dry out if left in place for too long. Known sensitivity to silicone.</td>
</tr>
<tr>
<td></td>
<td>Atraumatic to periwound skin</td>
<td>Use as contact layer on superficial low exuding wounds</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Conformable to body contours</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PHMB</td>
<td>Antimicrobial action</td>
<td>Low to high exuding wounds</td>
<td>Do not use on dry/necrotic wounds. Known sensitivity.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Critically colonised wounds or clinical signs of infection</td>
<td></td>
</tr>
<tr>
<td>Odour control (eg activated charcoal)</td>
<td>Odour absorption</td>
<td>Malodorous wounds (due to excess exudate) May require antimicrobial if due to increased bioburden</td>
<td>Do not use on dry wounds.</td>
</tr>
<tr>
<td>Protease modulating</td>
<td>Active or passive control of wound protease levels</td>
<td>Clean wounds that are not progressing despite correction of underlying causes, exclusion of infection and optimal wound care</td>
<td>Do not use on dry wounds or those with leathery eschar.</td>
</tr>
<tr>
<td>Silver</td>
<td>Antimicrobial action</td>
<td>Critically colonised wounds or clinical signs of infection</td>
<td>Some may cause discoloration. Known sensitivity. Discontinue after 2 weeks if no improvement and re-evaluate.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Low to high exuding wounds</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Combined presentation with foam and alginates/CMC for increased absorbency. Also in paste form</td>
<td></td>
</tr>
<tr>
<td>Polyurethane film</td>
<td>Moisture control</td>
<td>Primary dressing over superficial low exuding wounds Second dressing over alginate or hydrogel for rehydration of wound bed</td>
<td>Do not use on patients with fragile/compromised periwound skin. Do not use on moderate to high exuding wounds.</td>
</tr>
<tr>
<td></td>
<td>Breathable bacterial barrier Transparent (allow visualisation of wound)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Other more advanced dressings (eg collagen and bioengineered tissue products) may be considered for wounds that are hard to heal

*Wound dressings may contain alginates or CMC only; alginates may also be combined with CMC.
**TABLE 6: Wound management dressing guide**

<table>
<thead>
<tr>
<th>Type of tissue in the wound</th>
<th>Therapeutic goal</th>
<th>Role of dressing</th>
<th>Treatment options</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>Wound bed</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>preparation</td>
</tr>
<tr>
<td>Necrotic, black, dry</td>
<td>Remove devitalised tissue</td>
<td>Hydration of wound bed</td>
<td>Surgical or mechanical debridement</td>
</tr>
<tr>
<td>Do not attempt debridement if vascular insufficiency suspected</td>
<td>Promote autolytic debridement</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Keep dry and refer for vascular assessment</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sloughy, yellow, brown, black or grey</td>
<td>Remove slough</td>
<td>Rehydrate wound bed</td>
<td>Surgical or mechanical debridement</td>
</tr>
<tr>
<td>Dry to low exudate</td>
<td>Provide clean wound bed for granulation tissue</td>
<td>Control moisture balance</td>
<td>(consider antiseptic wound cleansing solution)</td>
</tr>
<tr>
<td></td>
<td>Promote autolytic debridement</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Granulating, clean, red</td>
<td>Promote granulation</td>
<td>Maintain moisture balance</td>
<td>Wound cleansing</td>
</tr>
<tr>
<td>Dry to low exudate</td>
<td>Provide healthy wound bed for epithelialisation</td>
<td>Protect new tissue growth</td>
<td>For deep wounds use cavity strips, rope or ribbon versions</td>
</tr>
<tr>
<td>Granulating, clean, red</td>
<td>Exudate management</td>
<td>Maintain moisture balance</td>
<td>Wound cleansing</td>
</tr>
<tr>
<td>Moderate to high exudate</td>
<td>Provide healthy wound bed for epithelialisation</td>
<td>Protect new tissue growth</td>
<td>(consider antiseptic wound cleansing solution)</td>
</tr>
<tr>
<td></td>
<td>Consider barrier products</td>
<td></td>
<td>Consider barrier products</td>
</tr>
<tr>
<td>Infected</td>
<td>Reduce bacterial load</td>
<td>Antimicrobial action</td>
<td>Wound cleansing</td>
</tr>
<tr>
<td>Low to high exudate</td>
<td>Exudate management</td>
<td>Moist wound healing</td>
<td>(consider antiseptic wound cleansing solution)</td>
</tr>
<tr>
<td>Odour control</td>
<td>Odour absorption</td>
<td>Consider barrier products</td>
<td></td>
</tr>
</tbody>
</table>

The purpose of this table is to provide guidance about appropriate dressings and should be used in conjunction with clinical judgement and local protocols. Where wounds contain mixed tissue types, it is important to consider the predominant factors affecting healing and address accordingly. Where infection is suspected it is important to regularly inspect the wound and to change the dressing frequently. Wound dressings should be used in combination with appropriate wound bed preparation, systemic antibiotic therapy, pressure offloading and diabetic control.
**Dressing application and wound monitoring**

Regularly reviewing a patient’s wound and dressing is vital. For infected or highly exuding wounds, a healthcare professional should inspect the wound and change the dressing daily, and then every two or three days once the infection is stable. A different type of dressing may be needed as the status of the wound changes.

Some patients, especially those with mobility issues or work commitments may prefer to change their dressings themselves, or have a relative or carer to do it. These patients should be advised about using aseptic technique and the wound should continue to be reviewed at regular intervals by the MDF or other healthcare team members. Patients should be encouraged to look out for signs of deterioration, such as increased pain, swelling, odour, purulence or septic symptoms. In some cases (eg in the first few days of antibiotic therapy) it is a good idea to mark the extent of any cellulitis with an indelible marker and tell the patient to contact the footcare team immediately if the redness moves substantially beyond the line.

When applying dressings:
- Avoid bandaging over toes as this may cause a tourniquet effect (instead, layer gauze over the toes and secure with a bandage from the metatarsal heads to a suitable point on foot)
- Use appropriate techniques (eg avoiding creases and being too bulky) and take care when dressing weight-bearing areas
- Avoid strong adhesive tapes on fragile skin
- Avoid tight bandaging at the fifth toe and the fifth metatarsal head (trim the bandage back)
- Ensure wound dead space is eliminated (eg use a dressing that conforms to the contours of the wound bed)
- Remember that footwear needs to accommodate any dressing.

Wounds should be cleansed at each dressing change and after debridement with a wound cleansing solution or saline. Cleansing can help remove devitalised tissue, re-balance the bioburden and reduce exudate to help prepare the wound bed for healing. It may also help to remove biofilms.

**Managing pain at dressing changes**

It is now acknowledged that many patients — even those with neuropathy or neuroischaemia — can feel pain due to their wound or a procedure. It is important to incorporate strategies to prevent trauma and minimise wound-related pain during dressing changes. This may include the use of soft silicone dressings and avoiding unnecessary manipulation of the wound. Remember also that patients who have lost the protective pain sensation are at greater risk of trauma at dressing change.

When appropriate, use low- or non-adherent dressings. If a dressing becomes encrusted or is difficult to remove, it is important to soak the dressing with saline or a wound irrigation solution and check the wound and surrounding skin for evidence of trauma and infection on dressing removal.

**Epithelial edge advancement**

It is important to debride the edges of the ulcer to remove potential physical barriers to the growth of the epithelium across the ulcer bed. The demarcation line between any necrotic tissue or gangrene and healthy tissue may become a site of infection. Similar problems can be seen when a gangrenous toe touches a healthy toe.

Conversely, ‘die-back’ is an abnormal response to over-aggressive sharp debridement. It involves necrosis at the wound edge and extends through previously healthy tissue.

If the wound does not respond to standard wound management interventions despite treatment of the underlying cause and
exclusion of infection, adjunctive therapies may be considered (Box 5).

**Pressure offloading**

In patients with peripheral neuropathy, it is important to offload at-risk areas of the foot in order to redistribute pressures evenly\(^\text{101}\). Inadequate offloading leads to tissue damage and ulceration. The gold standard is the total contact cast (TCC). This is a well-moulded, minimally padded foot and lower leg cast that distributes pressures evenly over the entire plantar surface of the foot. It ensures compliance because it is not easy for the patient to remove\(^\text{74}\). Using a TCC in patients with a unilateral uncomplicated plantar ulcer can reduce healing time by around six weeks\(^\text{37}\).

Disadvantages of TCCs include\(^\text{74}\):

- Must be applied by fully trained and experienced practitioners
- May cause skin irritation and further ulcers if applied inappropriately
- Prevents daily inspection (signs of spreading infection may go unnoticed)
- May disturb sleep
- Makes bathing difficult
- Patient may not tolerate it (especially in warm climates)
- May prevent patient’s ability to work
- Relatively high cost/low availability.

In patients with ischaemic or neuroischaemic ulcers, the priority is to protect the margins of the foot (eg using Scotchcast boots or healing sandals).

TCCs are contraindicated in patients with ischaemia because of the risk of inducing further DFUs\(^\text{102}\). They are also not appropriate for patients with infected DFUs or osteomyelitis because, unlike removable devices, they do not allow wound inspection\(^\text{74}\).

Removable devices (such as removable cast walkers, Scotchcast boots (Figures 15 and 16), healing sandals and crutches, walkers and wheelchairs) should be selected in these patients (see Table 7).

Removable devices may also be more pragmatic choices for less motivated patients because they allow patients to bathe and sleep more comfortably. However, using removable devices is complicated by patients not wearing the device as prescribed. This may account for their lower efficacy. One study found that patients wore their removable offloading device during less than 30% of their total daily activity\(^\text{103}\).

Examine footwear thoroughly in all patients at every clinic visit. The aim should be to provide a pressure-relieving device or to adapt existing footwear to accommodate pressure.

**TABLE 7: Offloading devices — alternatives to TCCs (adapted from\(^\text{73}\))**

<table>
<thead>
<tr>
<th>Type</th>
<th>Key points</th>
</tr>
</thead>
<tbody>
<tr>
<td>Removable cast walkers</td>
<td>— Similar pressure reduction to TCCs</td>
</tr>
<tr>
<td></td>
<td>— More acceptable to patients, but reduced healing rate compared with TCCs (Armstrong 2001)</td>
</tr>
<tr>
<td></td>
<td>— Can be used on infected and ischaemic wounds</td>
</tr>
<tr>
<td></td>
<td>— Easy to remove</td>
</tr>
<tr>
<td>Scotchcast boots</td>
<td>— Lighter and stronger alternative to plaster-of-Paris casts</td>
</tr>
<tr>
<td></td>
<td>— Padded cast covering the foot to the ankle</td>
</tr>
<tr>
<td></td>
<td>— Extensive practice experience, but no comparative data with the TCC</td>
</tr>
<tr>
<td></td>
<td>— Can be made non-removable</td>
</tr>
<tr>
<td>Healing sandals</td>
<td>— Designed to limit dorsiflexion of the metatarsophalangeal joints</td>
</tr>
<tr>
<td></td>
<td>— Improved distribution of metatarsal head pressures</td>
</tr>
<tr>
<td></td>
<td>— Lightweight, stable, reusable</td>
</tr>
<tr>
<td></td>
<td>— Can increase the risk of falling for patients with poor balance</td>
</tr>
<tr>
<td></td>
<td>— Requires time and expertise to produce and modify</td>
</tr>
<tr>
<td>Crutches, walkers and</td>
<td>— Provide complete offloading of the foot</td>
</tr>
<tr>
<td>wheelchairs</td>
<td>— Patients need good upper body strength</td>
</tr>
<tr>
<td></td>
<td>— Patients who do not perceive any limitation in function of the affected limb must understand the purpose of these devices and be motivated to use them</td>
</tr>
<tr>
<td></td>
<td>— Wheelchairs may be difficult to use in unmodified homes</td>
</tr>
</tbody>
</table>

In many countries some of the items listed are unavailable, but one can find inspired individuals adapting local resources to assist patients\(^\text{104}\).
Recommendations from the IWGDF\textsuperscript{26} on the use of offloading interventions in treating uncomplicated neuropathic foot ulcers are:

- Pressure relief should always be part of the treatment plan for an existing ulcer
- TCCs and non-removable walkers are the preferred interventions
- Forefoot offloading shoes or cast shoes may be used when above ankle devices are contraindicated
- Conventional or standard therapeutic footwear should not be used\textsuperscript{101}.

However, in many countries, recommended devices are not available and all that can be offered is cushioning constructed from items from local shops (e.g., kitchen sponges, upholstery foams etc.). In many regions of the world, walking barefoot or with poorly protective sandals is normal. Replacing these by advising shoe wear may be culturally unacceptable or create other foot problems\textsuperscript{105}. The use of trainers or sports shoes is recommended by some clinicians, which may provide another option to custom-built footwear where this is not accessible\textsuperscript{106}. Patients should also be advised to limit standing and walking and to rest with the foot elevated\textsuperscript{7}.

The introduction of medical insurance schemes that do not pay for preventative care has been a significant factor in lack of care in patients with diabetes in recent years. These schemes also limit what equipment can be offered to a patient.

The hallmark of an appropriately offloaded wound is a noticeable lack of undermining at the wound’s edge at follow up\textsuperscript{74}.

According to the IDF guideline, amputation should not be considered unless a detailed vascular assessment has been performed by vascular staff\textsuperscript{27}.

**Amputation may be indicated in the following circumstances\textsuperscript{27}:**

- Ischaemic rest pain that cannot be managed by analgesia or revascularisation
- A life-threatening foot infection that cannot be managed by other measures
- A non-healing ulcer that is accompanied by a higher burden of disease than would result from amputation. In some cases, for example, complications in a diabetic foot render it functionally useless and a well performed amputation is a better alternative for the patient.

Around half of patients who undergo an amputation will develop a further DFU on the contralateral limb within 18 months of amputation. The three-year mortality rate after a first amputation is 20–50\%\textsuperscript{107}. In a six-year follow-up study, almost 50\% of patients developed critical limb ischaemia in the contralateral limb, but the severity of the DFU and amputation level was significantly lower than in the unilateral limb. This may have been due to prompt intervention made possible by increased patient awareness\textsuperscript{108}.

Patients at high risk for ulceration (such as patients who have undergone an amputation for a DFU) should be reviewed 1–3 monthly by a foot protection team\textsuperscript{1}. At each review patients’ feet should be inspected and the need for vascular assessment reviewed. Provision should be made for intensified footcare education, specialist footwear and insoles, and skin and nail care. Special arrangements should be made for people with disabilities or immobility\textsuperscript{7}. The Scottish Intercollegiate Guidelines Network (SIGN) recommends specialist diabetes podiatrist input for patients with a history of amputation and ulceration\textsuperscript{37}.

Although amputation incidence may not reflect the quality of local healthcare delivery, there is a need for more consistent delivery of diabetes care\textsuperscript{70}, with the involvement of an MDFT and patient education.
Integrated care approach

**MULTIDISCIPLINARY FOOTCARE TEAM**

Evidence consistently highlights the benefits of MDFTs in the outcomes of DFUs. Over 11 years, one study found total amputations fell by 70% following improvements in footcare services, including multidisciplinary team work. However, in England around one-fifth of hospitals providing inpatient care for people with diabetes have no MDFT. Furthermore, in many areas of the country there are no clear pathways for referring patients at increased risk or high risk of developing DFUs, as recommended by NICE.

All the major guidelines recommend that patients identified with new DFUs should be referred to a dedicated MDFT. There are many different considered opinions about which disciplines should be incorporated in an MDFT.

The IDF recommends that a specialist footcare team will include doctors with a special interest in diabetes, people with educational skills and people with formal training in foot care (usually diabetes podiatrists and trained nurses). For comprehensive care, this team would be enhanced by vascular surgeons, orthopaedic surgeons, infection specialists, orthotists, social workers and psychologists (Box 6).

Guidelines aside, it will be local resources that dictate the skill mix and scope of any footcare team. In the UK there is a move towards having a core team of specialist diabetes podiatrists, medical specialty consultants, orthotists and surgeons, which works with additional relevant disciplines (such as nurses and general practitioners) almost in a virtual manner. The key is the ability to gain immediate access to relevant healthcare professionals (such as a vascular surgeon) as needed.

In many countries it is not only specialist equipment that may be unavailable, but also the specialist practitioners themselves, such as podiatrists, vascular surgeons or plaster technicians and so on. While the MDFT will be managing the ongoing challenges of DFU care, non-specialist practitioners can play a key role in the early detection of problems and prompt referral to the team.

**PATIENT FOOTCARE EDUCATION**

Patient education should be an integral part of management and prevention. Treatment outcomes will be directly influenced by patients’ knowledge of their own medical status, their ability to care for their wound and concordance with their treatment. It is vital that patients should know who to contact if a DFU develops or recurs, including emergency numbers for the MDFT and out-of-hours contact details.

The development of an ulcer is a major event and a sign of progressive disease. It is important to discuss the impact of the ulcer on life expectancy with the patient. Education should be offered on ways in which patients can help to improve outcomes by making lifestyle changes (eg smoking cessation) and working with practitioners to reduce the risk of recurrence and life-threatening complications.

A Cochrane systematic review found that educating people with diabetes about the need to look after their feet improves their footcare knowledge and behaviour in the short term. There was insufficient evidence that education alone, without any additional preventive measures, effectively reduces the occurrence of ulcers and amputations.

According to the IWGDF, patient education should be provided in several sessions using a variety of methods based on standard effective communication techniques. It is essential to evaluate whether the patient has understood the messages, is motivated to act and has sufficient self-care skills. Remember that elderly and disabled patients may need home or special care.

Practitioners should ensure patients understand the aims of treatment, how to recognise and report the signs and symptoms of (worsening) infection and the need for prompt treatment of new wounds.
Steps to avoid amputation: implementing a global wound care plan

A Diagnosis of diabetes (+/- peripheral sensory neuropathy)
AIM: Prevent the development of a DFU
1. Implement DFU prevention care plan that includes treatment of co-morbidities, good glycaemic control and pressure offloading
2. Annually perform general foot examination:
   — Use 10g monofilament to assess sensory status
   — Inspection of the feet for deformities
   — Inspection of footwear for wear and tear and foreign objects that may traumatise foot
   — Maintain skin hydration (consider emollient therapy) for skin health
   — Offer patient education on checking feet for trauma
3. Ensure regular review and provide patient education

B Development of DFU
AIM: Treat the ulcer and prevent infection
1. Determine cause of ulcer
2. Agree treatment aims with patient and implement wound care plan:
   — Debride and regularly cleanse the wound
   — Take appropriate tissue samples for culture if infection is suspected
   — Select dressings to maintain moist wound environment and manage exudate effectively
3. Initiate antibiotic treatment if infection suspected and consider topical antimicrobial therapy if increased bioburden is suspected
4. Review offloading device and ensure footwear accommodates dressing
5. Optimise glycaemic control for diabetes management
6. Refer for vascular assessment if clinically significant limb ischaemia is suspected
7. Offer patient education on how to self-manage and when to raise concerns

C Development of vascular disease
AIM: Prevent complications associated with ischaemia
1. Ensure early referral to vascular specialist for arterial reconstruction to improve blood flow in patients with an ischaemic or neuroischaemic ulcer
2. Optimise diabetes control

D Ulcer becomes infected
AIM: Prevent life- or limb-threatening complications
1. For superficial (mild) infections — treat with systemic antibiotics and consider topical antimicrobials in selected cases
2. For deep (moderate or severe) infections — treat with appropriately selected empiric systemic antibiotics, modified by the results of culture and sensitivity reports
3. Offload pressure correctly and optimise glycaemic control for diabetes management
4. Consider therapy directed at biofilm in wounds that are slow to heal

ACTIVE MANAGEMENT OF THE ULCER AND CO-MORBIDITIES SHOULD AIM TO PREVENT AMPUTATION
Where amputation is not avoidable:
1. Implement skin and wound care plan to manage surgical wound and optimise healing
2. Review regularly and implement prevention care plan to reduce risk of recurrence or further DFU on contralateral limb
REFERENCES


BEST PRACTICE GUIDELINES: WOUND MANAGEMENT IN DIABETIC FOOT ULCERS
REFERENCES


BEST PRACTICE GUIDELINES: WOUND MANAGEMENT IN DIABETIC FOOT ULCERS
98. Wolcott RD, Kennedy JP, Dowd SE. Regular debridement is the main tool for maintaining a healthy wound bed in most chronic wounds. J Wound Care 2009; 18(2): 54-56.